Glenmark Pharmaceuticals receives ANDA final approval for Tadalafil Tablets, 2.5 mg, 5 mg, 10 mg and 20 mg; and receives ANDA tentative approvals for Gabapentin Enacarbil Extended-Release Tablets, 300 mg and 600 mg and Apremilast Tablets, 10 mg, 20 mg and 30 mg
Glenmark becomes the first company to launch Remogliflozin + Vildagliptin fixed dose combination, at an affordable price for adults with Type 2 Diabetes in India
Glenmark Pharmaceuticals and Menarini enter into Exclusive Licensing Agreement for commercializing Ryaltris™ Nasal Spray across numerous markets throughout Europe.
Glenmark launches world's first Hypertension Awareness symbol, endorsed by Association of Physicians of India (API) & Hypertension Society of India (HSI)
Glenmark becomes the first pharmaceutical company in India to receive regulatory approval for oral antiviral Favipiravir, for the treatment of mild to moderate COVID-19
Glenmark Pharmaceuticals receives ANDA approval for Chlorzoxazone Tablets USP, 375 mg and 750 mg; Glenmark’s first ANDA approval out of their new U.S. facility
Glenmark to commence another new Phase 3 clinical trial on a combination of two anti-viral drugs Favipiravir and Umifenovir in hospitalized patients of moderate COVID-19 in India
Glenmark Pharmaceuticals and Hikma enter into an Exclusive Licensing Agreement for commercializing Ryaltris™ Seasonal Allergic Rhinitis Nasal Spray in the US
